News Archives

AMDA Statement Regarding the Management of “Myozyme” supply

Jan 17, 2009 | NEWS

The AMDA is writing to our Pompe patient community to let everyone know that the AMDA has been working closely with the IPA and Genzyme in order to get communication out to our patient population about the status of the Myozyme supply issue. Download complete...

PRESS RELEASE Priority access for children during Myozyme supply shortage

Jan 16, 2009 | NEWS

The European Medicines Agency’s (EMEA) Committee for Medicinal Products (CHMP) has recommended that infants, children and adolescents be given priority access to Myozyme (alglucosidase alfa), from Genzyme, during the expected supply shortage of the medicine over the...

IPA Statement Regarding The Management Of Myozyme Supply – Advice To Pompe Patients

Jan 14, 2009 | EDITORIALS

By: IPA posted on: January 14, 2009 Since the first market approval of Myozyme, the IPA has liaised directly with Genzyme LSD Therapeutics to insist that an adequate inventory of the product was kept to ensure continuous supply to all patients receiving the treatment;...

IPA Statement Regarding the Management of Myozyme Supply

Jan 14, 2009 | NEWS

Since the first market approval of Myozyme, the IPA has liaised directly with Genzyme LSD Therapeutics to insist that an adequate inventory of the product was kept to ensure continuous supply to all patients receiving the treatment; whether through their commercial or...

IPA Statement Regarding the Management of Myozyme Supply – Advice To Pompe Patients